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Summary 
A total of 72 patients with biopsy proven celiac disease (CD) (mean age 51, SD 15 yrs.) were 
screened for neurological disorders. Only 15.4 % of patients did not show any evidence for 
neurological disease. Medical history revealed a high prevalence of neurological disorders 
such as migraine (27.8 %), carpal tunnel syndrome (19.4 %), vestibular neuritis (8.3 %), 
seizures (5.6 %) and myelitis (2.8 %). Interestingly, 34.7 % of CD patients complained of 
psychiatric problems such as depression, personality changes or even psychosis. The physical 
examination yielded stance and gait problems in more than one third of the patients, while 
limb ataxia, intention tremor, and dysarthria were rather uncommon. Other motor features 
such as basal ganglia symptoms, pyramidal tract signs, tics and myoclonus were infrequent. 
34.7 % of CD patients showed deep sensory loss with reduced ankle reflexes in 13.9 %. 
Interestingly, vestibular deficits were present in 12.5 % of patients. So, gait disturbances in 
CD cannot only result from cerebellar ataxia, but also from proprioceptive or vestibular 
impairment.  
  
 
 
Abbreviations  
CD = celiac disease 
GS = gluten sensitivity 
AGA = antigliadin antibodies 
HLA = human leucocyte antigen  
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Introduction 
Celiac disease (CD) is associated with intolerance to dietary gluten, a component of cereals 
such as wheat, barley and rye. The syndrome is an immune mediated disease disease 
associated with the expression of the HLA class II DQ2 and DQ8. The pathogenesis is not 
completely understood but involves the infiltration of the lamina propria and the epithelial 
layer of the small bowel with T lymphocytes eventually leading to villous blunting and 
atrophy as well as crypt hyperplasia. These changes cause diarrhea with maldigestion and 
malabsorption. Numerous extraintestinal symptoms can occur, only some of which are related 
to malabsorption. Diagnosis is established by the demonstration of the characteristic 
histological changes in the duodenum 1-3. The term gluten sensitivity (GS) refers to patients 
with circulating antibodies to gliadin with no or only mild histological abnormalities.  
During the last years, there have been numerous reports on neurological complications 
affecting up to 6 to 8 % of CD patients 4;5, with cerebellar ataxia being the most frequent 
symptom 6. Several hypotheses have been postulated to explain neurological disease in CD 
including the existence of antineuronal antibodies e.g. directed against cerebellar Purkinje 
cells 7, the invasion of CD8 positive T cells into the nervous system 8 and deficiencies of 
neuroprotective substances due to malabsorption. Nevertheless, the link between CD and 
neurological symptoms not being elucidated to date, the issue is still a matter of debate 9. In 
most studies, patients with otherwise unexplained neurological symptoms were tested for the 
presence of circulating antibodies to gliadin (corresponding to the term ´gluten sensitivity´) 
and/or intestinal abnormalities 6;10. Only few studies have applied the inverse approach by 
primarily including patients with established CD.  Regarding the high prevalence of CD in the 
general population (1 to 200 inhabitants) 11, a random coincidence of CD and neurological 
disease cannot be ruled out. We therefore interviewed and examined unselected CD patients 
under primary medical/gastroenterological follow-up for neurological problems. 
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Patients & Methods 
CD patients. 72 patients were recruited from advertisements in the official journal of the 
German Celiac Society (Deutsche Zöliakie Gesellschaft DZG e.V., Stuttgart, Germany) or 
personal contact (GL) (male: N = 10, female: N = 62, mean age:  51 ± 15 years). Diagnosis of 
CD corresponded to Marsh stage III prior to the introduction of a gluten free diet with subtotal 
or total villous atrophy of the small intestine. Another 10 self-referring patients did not meet 
the diagnostic criteria of biopsy proven CD and had to be excluded from the study. At the 
time of the study, all patients followed a gluten free diet. All patients gave informed consent 
to participate in the study, which was approved by the ethics committees of the participating 
institutions. 
 
Clinical assessment. All participants underwent a standardized neurological examination 
procedure and were asked about their neurological and general medical history by means of a 
standard questionnaire.  
 
Results  
Medical history 
15.3 % of patients reported a positive family history of CD. 8.7 % suffered from IgA 
deficiency. 34.7 % of the CD patients complained of psychiatric problems such as depression, 
personality changes or even psychosis. 8.3 % of the individuals experienced attentional 
deficits causing problems in daily life. Two females reported a single episode of myelitis with 
inflammatory CSF changes. In both of them, there was no relapse of identical or distinct 
neurological symptoms. Another female patient suffered from personality changes, complex 
and generalised seizures with insufficient correspondence to anticonvulsive therapy, gait 
disturbances and cognitive impairment. The increase of thyreoperoxidase antibodies was 50 
fold while all other thyroid parameters were within the normal range. MRI showed discrete 
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white matter lesions on T2 weighted images. Under oral steroids, her clinical condition has 
ameliorated considerably.    
Other details of patients´ neurological history are listed in table 1. About one third of CD 
patients reported a history of migraine. Interestingly, many of these patients had noticed a 
decrease of the frequency and intensity of migraine after the introduction of a gluten free diet. 
Epilepsy included generalised and/or focal seizures. 
 
Neurological examination 
Problems of stance and gait were frequently found in CD patients (see table 2). Nevertheless, 
additional cerebellar features such as cerebellar oculomotor signs, limb ataxia or dysarthria 
were restricted to a minority of patients. Gait and stance problems can therefore not only 
result from cerebellar dysfunction but also from vestibular or proprioceptive problems. 
Reduced deep tendon reflexes (DTR) reflect motor neuropathy that was commonly mild and 
did not cause muscular weakness or even amyotrophy. Similarly, basal ganglia features were 
rather rare. None of the patients presented with a resting tremor. In total, only 15.4 % of 
patients did neither report nor show any neurological abnormalities. 
 
Discussion  
Neurological complications have first been reported to occur in approximately 6 % of adult 
CD patients by Cooke and Smith in 1966: The authors mainly described afferent or cerebellar 
ataxia in a group of 16 CD patients 12. Since then, many case reports have been published 
mentioning symptoms such as epilepsy (especially associated with occipital calcifications and 
folate deficiency), peripheral neuropathy, chronic progressive leukencephalopathy, brain stem 
encephalitis, myositis, neuromyotonia, myasthenic syndromes, myelopathy, multiple sclerosis 
and dementia with brain atrophy 5;13-19. Neuropsychiatric features of GS/CD include 
depression, attentional deficits, autism, and schizophrenia 5;20-23.  
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Systematic approaches including larger patient numbers are limited. Additionally, many of 
these publications do not focus on neurological disease in biopsy proven CD but investigate 
the frequency of antigliadin antibodies (AGA) in neurological patients: In a UK study, AGA 
were positive in 57 % of 53 patients with unexplained neurological symptoms as compared to 
5 % of patients with defined neurological syndromes. Interestingly, highly positive rates in the 
control population (12 %) were not further addressed by the authors 2. Lock and colleagues 
studied AGA in British patients with ´idiopathic´ cerebellar ataxia, unexplained neuropathy, 
hereditary ataxia and healthy blood donors. They found positive AGA (IgA and/or IgG) in 40 
% of idiopathic ataxia, 34 % of neuropathy, 43 % of hereditay ataxia and 17 % of healthy 
blood donors 24. Lahat and colleagues screened children with neurological disorders including 
epilepsy and migraine for AGA: positive AGA IgG were found in 13 % of 167 patients and 9 
% of controls. None had AGA IgA or antiendomysial antibodies 25. When comparing the 
presence of AGA in multiple system atrophy (MSA) and Parkinson´s disease, AGA IgA were 
restricted to MSA (18.7 %). The authors explained their findings with a possible role of GS in 
the pathogenesis of MSA. Since the diagnosis of MSA can only be confirmed by 
neuropathology, they speculated alternatively that GS might be responsible for  phenotypes 
resembling MSA 26. The same group also reported on CD with full-blown villous atrophy in 
12.5 % of 24 Italian patients with otherwise unexplained cerebellar ataxia 27.  
Certain discrepancies between different studies suggest a certain observation bias when 
exclusively focusing on primary neurological patients. Indeed, the association of neurological 
disease and CD appears less prominent in studies of primary CD cohorts: In a retrospective 
analysis, 189 among 620 patients attending a British celiac clinic presented with 263 distinct 
neurological and/or psychiatric conditions. The most common were depression (11.5 %), 
epilepsy (4.0 %), migraine (3.2 %) and carpal tunnel syndrome (CTS) (2.4 %) 28. So, the 
present findings are in accordance to these published data. Nevertheless, the prevalence in our 
CD sample was much higher than in the British cohort. A possible explanation could be the 
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recruitment properties of our study: CD patients with a history of neurological problems 
would have a greater interest to participate in such a study than patients without any 
neurological complaint. This hypothesis is supported by the low number of patients without 
any neurological abnormalities (15.4 %). When inquiring children, adolescents and young 
adults with CD about neurological complaints, Zelnik and coworkers found them to be more 
prone to develop neurological symptoms as compared to age-matched controls (51.4 % vs. 
19.9 %) 29. Symptoms were the following: hypotonia, developmental delay, learning disorders 
and attention deficit hyperactivity disorder (ADHD), headache and cerebellar ataxia. 
Similarly, Luostarinen detected neurological abnormalities in 7 % of 144 newly diagnosed 
CD cases over a three year period presenting with neuropathy, memory deficits, ataxia, 
epilepsy, and parkinsonism 29;30. 
In the current study, gait disturbances were obvious in more than one third of CD patients. 
Nevertheless, only a minority presented with ataxia resulting from cerebellar disease. 
Surprisingly, more than 8 % of our patients reported on episodes with dizziness and vestibular 
problems and VOR impairment was obvious in 12.5 %. So, vestibular dysfunction is likely to 
contribute to the unsteadiness a least in some of the patients. The one year prevalence of 
vestibular dysfunction and dizziness is up to 4.9 % 31. The high rate of vestibular problems 
cannot be easily explained. There have been no neuropathological investigations of the VIII 
cranial nerve in CD. Further post mortem studies will be necessary to assess vestibular 
susceptibility to inflammation in CD.  
Problems of stance and gait might also be related to proprioceptive deficits that are common 
among CD patients. Indeed, degeneration of the dorsal columns has been observed in post 
mortem material of CD patients 6. Alternatively, the combination of reduced tendon reflexes 
and sensory deficits in CD patients is compatible with peripheral neuropathy. Actually, 
peripheral neuropathy of the axonal or demyelinating type has often been reported in CD 
patients 32-34. Chin and colleagues found 5 % of patients with otherwise unexplained 
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neuropathy to suffer from CD 35. A Swedish study yielded neuropathy in 10 % of CD patients 
30. Furthermore, an analysis of the Swedish national registers yielded a significant relationship 
of CD and neuropathy: primary CD was associated with later neuropathy and prior 
neuropathy was found to be linked to subsequent CD 36. In a French study, the mean 
incidence rate of CTS per 1000 person-years did not exceed 1.7 in working women and 0.6 in 
men 37. Actually, the high prevalence of CTS among CD patients (19.4 %) may reflect 
pathogenic similarities between CTS and peripheral neuropathy.  
Another feature in CD patients is epilepsy that was rather rare in our cohort. In the contrary, 
almost 30 % of patients stated a history of migraine. In the general population, only 18 % of 
women and 6 % of men are affected by recurrent migraine attacks. Interestingly, many 
patients reported a significant decrease of the amplitude and frequency of migraine attacks 
after the introduction of a gluten free diet. Inflammation is an important component of most 
migraine models and anti-inflammatory drugs are very effective in treating migraine attacks. 
Modifications of the immune system including the expression of certain cytokine profiles 
have been claimed to act as risk factors for migraine. In these models, cytokines act as 
powerful pain mediators in neurovascular inflammation 38.  
In CD, the mechanisms leading to neurological disease are not yet understood. Deficiencies of 
folic acid, vitamin E and biopterin have formerly been implicated in the pathogenesis of 
neurological disease in CD. However, replacement therapy does not resolve clinical 
symptoms in the majority of cases. Furthermore, hypovitaminosis rarely causes overt 
abnormalities in CD patients and most neurological patients with CD do not show evidence 
for any nutritional deficiencies 10;27;32;33;39. Besides, all our patients followed a gluten free diet 
and did not have signs of malabsorption. Neuropathological studies of CD brains point to 
immune mediated mechanisms with infiltrating lymphocytes in the central and peripheral 
nervous system 6. CSF analysis performed in 12.5 % of patients was abnormal in about one 
third of them. Abnormalities consisted of increased cell count, elevated protein contents and 
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positive oligoclonal bands. These findings give support to the immune hypothesis of 
neurological involvement in CD.  
Taken together, the high prevalence of neurological manifestations in CD is striking and must 
be considered more than accidental. It is true that pathogenic mechanisms linking CD to the 
nervous system have not yet been identified. Regarding this considerable clinical variability, 
not a single, but many different pathogenic mechanisms are likely to contribute to 
neurological dysfunction in CD.    
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Table 1. Neurological history of CD patients. 
 
 
Neurological Disorder CD patients (N = 72) 
[%] 
Migraine 27.8 
Carpal tunnel syndrome 19.4 
Bladder dysfunction 13.9 
Vestibular disturbances with dizziness 8.3 
Seizures  5.6 
Myelitis 2.8 
Hashimoto´s encephalopathy 1.4 
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Table 2. Neurological symptoms in CD patients. 
 
 
 
CD patients (N = 72)  
[%] 
Oculomotor features 
Impaired smooth pursuit 20.8 
Square wave jerks (fixation instability) 15.3 
Vestibular deficits (impaired vestibulo-
ocular reflex (VOR)) 12.5 
Gaze evoked nystagmus 5.6 
Double vision 4.2 
Slow saccades 2.8 
Gaze palsy 2.8 
Spontaneous nystagmus 1.4 
 
 
 
Peripheral motor system 
Reduced deep tendon reflexes 13.9 
Amyotrophy 1.4 
Somatosensory system 
Impaired proprioception 34.7 
Impaired exteroception 5.6 
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Movement disorders 
Ataxia of stance 34.7 
Ataxia of gait 27.8 
Limb ataxia 12.5 
Cog wheel rigidity 12.5 
Dysarthria 5.6 
 
Dystonia 4.2 
Akinesia 2.8 
Pyramidal tract signs  4.2 
Spasticity 4.2 
Tics 2.8 
Intention tremor 2.8 
Myoclonus 1.4 
 
 
 
 
 
 
 
 
 
 
 16
Bürk et al., Neurological disease in CD  17 
  
 17
